eXoZymes Inc. (EXOZ)
EXOZ trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/2010788/000164117225001744/0001641172-25-001744-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | EXOZ on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0002010788 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | NV |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $70K |
| Net income | -$2.0M |
| Operating income | -$1.8M |
| Net margin | -2909.1% |
| Operating margin | -2563.5% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $67K |
| Total assets | $3.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 529.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Management has concluded that the Company's existing working capital is not sufficient to fund operations for twelve months from the date these condensed unaudited consolidated financial statements are issued and that substantial doubt exists about its ability to continue as a going concern due to anticipated funding shortfalls and the Company's pre-revenue status." | 10-Q 2026-11-13 |
| Cash and burn | $5.7M cash; operating cash flow -$1.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 9,439,915 (2026-11-13); 8,387,250 a year earlier. | Cover page 2026-11-13 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the market | Latest 2026-06-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | RBSM LLP, LAS VEGAS, Nevada, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $6K, sold $15K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$2.9M | -$1.6M | $5.7M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$2.4M | -$1.5M | $1.4M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2025 2025-12-31 | Not filed | -$2.7M | -$2.0M | $3.0M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$2.3M | -$1.9M | $5.1M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$2.4M | -$1.5M | $7.0M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$1.9M | -$1.1M | $8.5M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2024 2024-12-31 | Not filed | -$1.8M | -$5.7M | $9.7M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | Not filed | -$1.7M | -$542K | $234K | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2026-11-06 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-10-09 |
| Latest proxy | DEFA14A | 2026-09-28 |
Source: SEC EDGAR submissions feed, 131 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.0% |
| 1 month | -16.6% |
| 3 months | -36.2% |
| Year to date | -64.9% |
| 1 year | -76.6% |
| From 52-week high | -76.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ELUT | Elutia Inc. | $0.8229 | +0.35% | $36.5M |
| CRBU | Caribou Biosciences Inc. | $0.3528 | -2.51% | $38.1M |
| TIL | Instil Bio Inc. | $5.75 | -5.43% | $39.0M |
| KLRS | Kalaris Therapeutics Inc. | $1.46 | -7.30% | $34.8M |
| IMA | ImageneBio Inc. | $3.20 | -7.78% | $39.9M |
| LONA | LeonaBio Inc. | $3.23 | -6.92% | $30.4M |
| INMB | INmune Bio Inc. | $0.9464 | -9.87% | $29.3M |
| CVM | Cel-Sci Corporation | $1.66 | +29.69% | $29.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier